ArticleDiscover oncology2025
Comprehensive analysis of a machine learning prognostic model for the interaction between mitochondrial function and lactylation in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondrial function and lactylation play important roles in the development of lung adenocarcinoma (LUAD). However, the impact of their interaction on the prognosis of LUAD still needs further investigation.
methodsA prognostic model was developed via machine learning algorithms. LUAD patients were grouped based on the median risk score, and the differences between groups in tumor biological characteristics, tumor immunity, and drug sensitivity were analyzed. Consensus clustering analysis was performed, and a nomogram survival prediction model was constructed.
resultsWe constructed an optimal prognostic model with 11 valuable signature genes. LUAD patients were classified into high- and low-risk groups based on the median risk score. The high-risk group was enriched in tumor proliferation-related pathways and glycolysis, while the low-risk group was associated with inflammation and immune response-related pathways. The high-risk group had higher tumor stemness, mutation burden, and poorer survival prognosis than the low-risk group. Immune microenvironment and drug sensitivity differed between the two groups. Furthermore, consensus clustering can divide LUAD patients into C1 and C2 subtypes, corresponding to low- and high-risk groups, respectively.
conclusionThis study provides a reliable prognostic model for the risk assessment of LUAD. It reveals the distinct biological characteristics and prognostic differences in LUAD patients with different clinical outcomes, providing a potential theoretical basis for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.